• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Israeli Study Proves Cannabis Can Be Safe and Effective for Cancer Patients

February 27, 2018

 

For the first time, a major scientific study has confirmed what cannabis advocates have known for decades: that cannabis can be a safe and effective palliative treatment in patients suffering from the debilitating effects of cancer.

 

The article, “Prospective Analysis Of Safety And Efficacy Of Medical Cannabis In Large Unselected Population Of Patients With Cancer” just published in the European Journal of Internal Medicine, studied thousands of cancer patients at Tikun Olam's clinics in Israel.

 

 

Tikun Olam, a leading cannabis brand in Israel and globally, has been operating as a commercial venture for over 10 years researching, developing and providing efficacious, data-based cannabis treatments to help sufferers.

 

As Tikun Olam’s products have been used since 2010 in ongoing clinical trials in Israel’s regulated medical cannabis market, it's no wonder they were a part of this recent study as well.  

 

Many cannabis investors may already be familiar with Tikun Olam from the company's partnerships with MariMed Inc. (OTC:MRMD) in the U.S. and MedReleaf Corp. (TSX:LEAF) (OTC:MEDFF) in Canada

 

The patients in the study were prescribed cannabis for their “malignancy-related symptoms,” mainly sleep problems, pain, nausea, and decreased appetite. All patients were prescribed one or more of Tikun Olam’s proprietary cannabis strains, which were developed to address specific symptoms. Overall, the study encompassed 2,970 cancer patients, with an average age of 60, and treated between the years 2015 and 2017. 

 

Tikun Olam published the following: 95.9% of respondents reported an improvement in their condition through use of medical cannabis, leading the study’s authors to conclude that “Cannabis as a palliative treatment for cancer patients is a well-tolerated, effective and safe option.” In medical terms, palliative treatment in cancer patients is aimed mainly to alleviate pain and nausea.

 

The article also offers hope in the fight against the U.S. opioid epidemic. While opioids were the most consumed drug by patients at intake, at six months, 36% had stopped taking opioids entirely, and an additional 10% decreased their dosage. This is especially significant because 51% of the patients studied were suffering from Stage 4 cancers, and 52% reported their pain at an intense (8/10) level.

 

“The data establishes that cannabis is effective treatment for the most acute symptoms of cancer, such as pain, which often requires the use of opioids,” said Lihi Bar-Lev Schleider of Tikun Olam and lead author of the article.

 

Side effects were sparse and minor: the most common reported at one month were dizziness (8%), dry mouth (7.3%), increased appetite (3.6%), sleepiness (3.3%) and psychoactive effect (2.8%).

 

On the other hand, improvement was undisputed: at six months, 50.8% of respondents reported at least a significant improvement, 45.1% reported moderate or slight improvement and only 4.0% did not experience a positive effect.

 

As stated above, this study has confirmed what medical marijuana advocates have known for years.

 

To stay up to date with important developments in the cannabis industry, be sure to subscribe to one or more of our free email newsletters. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, and Instagram!

 

D/M/O

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.